posted by mike kraft
on Tue, 2024-04-09 09:32
Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.
...
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
- Private group -
